leadf
logo-loader
viewVolitionRx

VolitionRx CEO to present coronavirus white blood cell research at Maxim Group virtual conference

Cameron Reynolds plans to talk about Volition’s research on white blood cells and their predictive potential regarding the coronavirus

Coronavirus graphic
VolitionRx is currently clinically testing whether elevated levels of neuroendocrine tumors in the blood are predictive of complications arising from viral infections such as COVID-19

VolitionRx Limited (NYSEAMERICAN:VNRX) announced Wednesday that CEO Cameron Reynolds has been invited to give a presentation on coronavirus testing Wednesday at The Role of Cell Therapy and Clarity on Testing Conference.

The virtual event, put on by the Maxim Group, runs from 10 am to 2 pm ET. Reynolds is part of a panel discussion titled “Testing & Susceptibility - Clearing the Air,” set to begin at noon.

Reynolds plans to talk about Volition’s research on white blood cells and their predictive potential regarding the coronavirus.

READ: VolitionRx closes $13.8M public offering to fund product development and clinical studies

Under normal circumstances, neutrophil extracellular traps (NETs) are formed by white blood cells to catch and trap invading viruses by ejecting chromatin materials. Viruses like SARS and pneumonia, though, are associated with a hyperimmune response that sees white blood cells eject massive amounts of NETs, which is damaging to the lungs.

VolitionRx is currently clinically testing whether elevated levels of neuroendocrine tumors (NETs) in the blood are predictive of complications arising from viral infections such as COVID-19. 

So far, a proof of concept study of 34 coronavirus patients and 50 control group subjects revealed that nucleosomes, a basic structural unit of DNA, were highly elevated in those with the virus.

A preliminary study showed an area under the curve (AUC) — a measure of drug exposure — for one of its NU.Q assays of 98.7% for PCR positive COVID versus the control group with 100% sensitivity and 94% specificity. A second assay showed an AUC of 86.2%.

The company plans to use the results of this trial and other ongoing studies to further its efforts to develop a clinically useful product to help mitigate the pandemic, the company said.

Contact Andrew Kessel at [email protected]

Follow him on Twitter @andrew_kessel

Quick facts: VolitionRx

Price: 2.98 USD

NYSEMKT:VNRX
Market: NYSEMKT
Market Cap: $142.8 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of VolitionRx named herein, including the promotion by the Company of VolitionRx in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

VolitionRx hosts virtual capital markets day event to discuss upcoming...

VolitionRx Limited (NYSE AMERICAN: VNRX) CEO Cameron Reynolds the Austin, Texas-based epigenetics company hosted a virtual capital markets day event on Tuesday, October 20, 2020. Reynolds says the presentation focused on new data, and the launch and commercial roll out of the company's first...

1 week, 2 days ago

2 min read